Back to results
US 2019/0292237 A1Published application
Compositions comprising a p75 tumor necrosis factor receptor/ig fusion protein
AssigneeImmunex Corporation
InventorsWayne Richard Gombotz, Richard L. Remmele, JR.
Life of this patent
Estimating the term…
Abstract
The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.
Claims31
-30. (canceled)
A method of treating rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis in a subject in need thereof, the method comprising administering to the subject a weekly single subcutaneous dose of about 10-80 mg of etanercept,
- wherein the etanercept is administered in a pharmaceutical composition comprising about 50 mg/ml etanercept, an excipient, and a buffer;
- wherein the excipient is lysine and the buffer is sodium citrate;
- wherein the pharmaceutical composition does not comprise arginine;
- and
- wherein the composition has not been lyophilized.
2 more elements
A method comprising
- (a) forming an aqueous pharmaceutical composition comprising etanercept, an excipient and a buffer, and
- (b) storing the aqueous pharmaceutical composition as a liquid for three months at 2-8° C., wherein the excipient is lysine, the buffer is sodium citrate, and
- wherein the aqueous pharmaceutical composition does not comprise arginine.
A method comprising
- (a) forming an aqueous pharmaceutical composition comprising etanercept, an excipient and a buffer,
- (b) freezing the aqueous pharmaceutical composition of step (a), and
- (c) thawing the composition of step (b),
- wherein the excipient is lysine, the buffer is sodium citrate, and wherein the aqueous pharmaceutical composition does not comprise arginine.
1 more element
Dependencies are inferred from the claim text.